Genomic studies, focused on distinct gene sequences and mutations, unraveled the great molecular heterogeneity in AML patients [2]: in ~30–35% of cases, the most prevalent genetic mutations involve nucleophosmin 1 (NPM1), occurring in approximately one-third of newly diagnosed cases across age groups [5]. This evidence concerns the gene NPM1 and acute myeloid leukemia.